{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T10:16:41Z","timestamp":1793873801604,"version":"4.6.1"},"reference-count":45,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,1]]},"abstract":"<jats:p>MLH1\/PMS2 loss due to epigenetic hypermethylation of the <jats:italic toggle=\"yes\">MLH1<\/jats:italic> promoter is the most common cause of mismatch repair deficiency in endometrial carcinoma, and typically provides reassurance against an associated germline mutation. To further characterize the genetic features of MLH1\/PMS2-deficient endometrial cancers, the departmental database was searched for cases with dual MLH1\/PMS2 loss and retained MSH2\/6 expression which underwent <jats:italic toggle=\"yes\">MLH1<\/jats:italic> hypermethylation testing. Genetic testing results were obtained when available. One hundred seventeen endometrial cancers met inclusion criteria: 100 (85%) were <jats:italic toggle=\"yes\">MLH1<\/jats:italic>-hypermethylated, 3 (3%) were low-level\/borderline, 7 (6%) were nonmethylated, and 7 (6%) were insufficient for testing. Sixteen cases (12 <jats:italic toggle=\"yes\">MLH1<\/jats:italic>-hypermethylated, 3 nonmethylated, and 1 insufficient for testing) underwent germline testing, 6 of which (37.5%) demonstrated germline variants of unknown significance (VUS) (<jats:italic toggle=\"yes\">MSH6<\/jats:italic>, <jats:italic toggle=\"yes\">PMS2<\/jats:italic>, <jats:italic toggle=\"yes\">POLD1<\/jats:italic>, <jats:italic toggle=\"yes\">BRIP1<\/jats:italic>, <jats:italic toggle=\"yes\">RAD51D<\/jats:italic>, <jats:italic toggle=\"yes\">CHEK2<\/jats:italic>) but no known deleterious mutations. Notably, however, the patients harboring the <jats:italic toggle=\"yes\">MSH6<\/jats:italic> and <jats:italic toggle=\"yes\">PMS2<\/jats:italic> germline VUS had clinical features concerning for Lynch syndrome. One nonmethylated, germline-normal case underwent somatic tumor testing, and demonstrated a somatic <jats:italic toggle=\"yes\">MLH1<\/jats:italic> mutation. In summary, <jats:italic toggle=\"yes\">MLH1-<\/jats:italic>hypermethylation accounts for the vast majority of MLH1\/PMS2-deficient cancers in a universally screened population, although <jats:italic toggle=\"yes\">MLH1<\/jats:italic> somatic and germline mutations can occur. Occasionally, patients with <jats:italic toggle=\"yes\">MLH1-<\/jats:italic>hypermethlated tumors also bear germline VUS in other mismatch repair genes as well as genes implicated in other hereditary cancer syndromes, but their clinical relevance is unclear. Family and personal cancer histories must always be evaluated to determine the need for germline testing in women with loss of MLH1\/PMS2, even in the setting of hypermethylation.<\/jats:p>","DOI":"10.1097\/pgp.0000000000000767","type":"journal-article","created":{"date-parts":[[2021,2,25]],"date-time":"2021-02-25T02:20:54Z","timestamp":1614219654000},"page":"1-11","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":11,"title":["MLH1\/PMS2-deficient Endometrial Carcinomas in a Universally Screened Population: MLH1 Hypermethylation and Germline Mutation Status"],"prefix":"10.1097","volume":"41","author":[{"given":"Brett","family":"Kurpiel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martha S.","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mansoor","family":"Mubeen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kari L.","family":"Ring","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan C.","family":"Modesitt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher A.","family":"Moskaluk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne M.","family":"Mills","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2021,2,11]]},"reference":[{"key":"R1-20250802","doi-asserted-by":"crossref","first-page":"2785","DOI":"10.1002\/cncr.31551","article-title":"Annual Report to the Nation on the Status of Cancer, part I: National cancer statistics","volume":"124","author":"Cronin","year":"2018","journal-title":"Cancer"},{"key":"R2-20250802","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1177\/107327480901600103","article-title":"Endometrial cancer and Lynch syndrome: clinical and pathologic considerations","volume":"16","author":"Meyer","year":"2009","journal-title":"Cancer Control"},{"key":"R3-20250802","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1007\/s10689-012-9591-x","article-title":"EPCAM deletion carriers constitute a unique subgroup of Lynch syndrome patients","volume":"12","author":"Ligtenberg","year":"2013","journal-title":"Fam Cancer"},{"key":"R4-20250802","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1002\/gcc.20678","article-title":"Germline hypermethylation of MLH1 and EPCAM deletions are a frequent cause of Lynch syndrome","volume":"48","author":"Niessen","year":"2009","journal-title":"Genes Chromosomes Cancer"},{"key":"R5-20250802","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1158\/1940-6207.CAPR-10-0345","article-title":"The search for unaffected individuals with Lynch syndrome: do the ends justify the means?","volume":"4","author":"Hampel","year":"2011","journal-title":"Cancer Prev Res (Phila)"},{"key":"R6-20250802","doi-asserted-by":"crossref","first-page":"e35","DOI":"10.1097\/PAS.0000000000000608","article-title":"Lynch Syndrome screening in the gynecologic tract: current state of the art","volume":"40","author":"Mills","year":"2016","journal-title":"Am J Surg Pathol"},{"key":"R7-20250802","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1007\/s10689-013-9615-1","article-title":"Cancer risk in Lynch Syndrome","volume":"12","author":"Barrow","year":"2013","journal-title":"Fam Cancer"},{"key":"R8-20250802","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1053\/j.gastro.2009.07.039","article-title":"Calculation of risk of colorectal and endometrial cancer among patients with Lynch syndrome","volume":"137","author":"Stoffel","year":"2009","journal-title":"Gastroenterology"},{"key":"R9-20250802","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1200\/JCO.2014.58.1322","article-title":"Hereditary colorectal cancer syndromes: American Society of Clinical Oncology Clinical Practice Guideline endorsement of the familial risk-colorectal cancer: European Society for Medical Oncology Clinical Practice Guidelines","volume":"33","author":"Stoffel","year":"2015","journal-title":"J Clin Oncol"},{"key":"R10-20250802","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1002\/ijc.2910640613","article-title":"Life-time risk of different cancers in hereditary non-polyposis colorectal cancer (HNPCC) syndrome","volume":"64","author":"Aarnio","year":"1995","journal-title":"Int J Cancer"},{"key":"R11-20250802","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1136\/jmg.2004.024299","article-title":"Risk of colorectal and endometrial cancer for carriers of mutations of the hMLH1 and hMSH2 gene: correction for ascertainment","volume":"42","author":"Quehenberger","year":"2005","journal-title":"J Med Genet"},{"key":"R12-20250802","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1097\/IGC.0b013e31828eed9c","article-title":"Women 50 years or younger with endometrial cancer: the argument for universal mismatch repair screening and potential for targeted therapeutics","volume":"23","author":"Ring","year":"2013","journal-title":"Int J Gynecol Cancer"},{"key":"R13-20250802","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1097\/PAS.0000000000000321","article-title":"Lynch syndrome screening should be considered for all patients with newly diagnosed endometrial cancer","volume":"38","author":"Mills","year":"2014","journal-title":"Am J Surg Pathol"},{"key":"R14-20250802","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.humpath.2017.10.022","article-title":"Universal screening for Lynch syndrome in endometrial cancers: frequency of germline mutations and identification of patients with Lynch-like syndrome","volume":"70","author":"Dillon","year":"2017","journal-title":"Hum Pathol"},{"key":"R15-20250802","doi-asserted-by":"crossref","first-page":"293","DOI":"10.2353\/jmoldx.2008.080031","article-title":"Immunohistochemistry versus microsatellite instability testing for screening colorectal cancer patients at risk for hereditary nonpolyposis colorectal cancer syndrome. Part I. The utility of immunohistochemistry","volume":"10","author":"Shia","year":"2008","journal-title":"J Mol Diagn"},{"key":"R16-20250802","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1097\/01.pas.0000213428.61374.06","article-title":"Utility of immunohistochemistry in predicting microsatellite instability in endometrial carcinoma","volume":"31","author":"Modica","year":"2007","journal-title":"Am J Surg Pathol"},{"key":"R17-20250802","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1097\/PAS.0b013e31820a091d","article-title":"Immunohistochemical staining for DNA mismatch repair proteins in intestinal tract carcinoma: how reliable are biopsy samples?","volume":"35","author":"Shia","year":"2011","journal-title":"Am J Surg Pathol"},{"key":"R18-20250802","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1093\/annonc\/mdw542","article-title":"Practical guidance for mismatch repair-deficiency testing in endometrial cancer","volume":"28","author":"Stelloo","year":"2017","journal-title":"Ann Oncol"},{"key":"R19-20250802","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/s41379-018-0125-4","article-title":"Targeted next-generation sequencing in the detection of mismatch repair deficiency in endometrial cancers","volume":"32","author":"Dong","year":"2019","journal-title":"Mod Pathol"},{"key":"R20-20250802","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1097\/PAS.0000000000000544","article-title":"Clinicopathologic comparison of Lynch syndrome-associated and \u201cLynch-like\u201d endometrial carcinomas identified on universal screening using mismatch repair protein immunohistochemistry","volume":"40","author":"Mills","year":"2016","journal-title":"Am J Surg Pathol"},{"key":"R21-20250802","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.ygyno.2013.04.022","article-title":"Implementation of tumor testing for lynch syndrome in endometrial cancers at a large academic medical center","volume":"130","author":"Moline","year":"2013","journal-title":"Gynecol Oncol"},{"key":"R22-20250802","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.4161\/15592294.2014.970080","article-title":"MLH1 constitutional and somatic methylation in patients with MLH1 negative tumors fulfilling the revised Bethesda criteria","volume":"9","author":"Crucianelli","year":"2014","journal-title":"Epigenetics"},{"key":"R23-20250802","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1136\/jmedgenet-2014-102552","article-title":"Tumour MLH1 promoter region methylation testing is an effective prescreen for Lynch Syndrome (HNPCC)","volume":"51","author":"Newton","year":"2014","journal-title":"J Med Genet"},{"key":"R24-20250802","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1097\/PAS.0000000000000606","article-title":"Isolated loss of PMS2 immunohistochemical expression is frequently caused by heterogenous MLH1 promoter hypermethylation in Lynch syndrome screening for endometrial cancer patients","volume":"40","author":"Kato","year":"2016","journal-title":"Am J Surg Pathol"},{"key":"R25-20250802","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1038\/modpathol.2016.135","article-title":"Germline multi-gene hereditary cancer panel testing in an unselected endometrial cancer cohort","volume":"29","author":"Ring","year":"2016","journal-title":"Mod Pathol"},{"key":"R26-20250802","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s10689-019-00151-7","article-title":"MLH1 promoter hypermethylation: are you absolutely sure about the absence of MLH1 germline mutation? About a new case","volume":"19","author":"Kientz","year":"2020","journal-title":"Fam Cancer"},{"key":"R27-20250802","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1002\/path.2263","article-title":"Coexisting somatic promoter hypermethylation and pathogenic MLH1 germline mutation in Lynch syndrome","volume":"214","author":"Rahner","year":"2008","journal-title":"J Pathol"},{"key":"R28-20250802","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1186\/s12885-018-4489-0","article-title":"Lynch syndrome-associated endometrial carcinoma with MLH1 germline mutation and MLH1 promoter hypermethylation: a case report and literature review","volume":"18","author":"Yokoyama","year":"2018","journal-title":"BMC Cancer"},{"key":"R29-20250802","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s10689-019-00145-5","article-title":"Novel candidates in early-onset familial colorectal cancer","volume":"19","author":"Jansen","year":"2020","journal-title":"Fam Cancer"},{"key":"R30-20250802","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1038\/gim.2017.185","article-title":"Risk of colorectal cancer for carriers of a germ-line mutation in POLE or POLD1","volume":"20","author":"Buchanan","year":"2018","journal-title":"Genet Med"},{"key":"R31-20250802","doi-asserted-by":"crossref","first-page":"1308.e1","DOI":"10.1053\/j.gastro.2014.08.041","article-title":"Colon and endometrial cancers with mismatch repair deficiency can arise from somatic, rather than germline, mutations","volume":"147","author":"Haraldsdottir","year":"2014","journal-title":"Gastroenterology"},{"key":"R32-20250802","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.ygyno.2015.12.031","article-title":"Mutation spectrum of POLE and POLD1 mutations in South East Asian women presenting with grade 3 endometrioid endometrial carcinomas","volume":"141","author":"Wong","year":"2016","journal-title":"Gynecol Oncol"},{"key":"R33-20250802","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1002\/cncr.30498","article-title":"A study of over 35,000 women with breast cancer tested with a 25-gene panel of hereditary cancer genes","volume":"123","author":"Buys","year":"2017","journal-title":"Cancer"},{"key":"R34-20250802","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1002\/cncr.29010","article-title":"Frequency of mutations in individuals with breast cancer referred for BRCA1 and BRCA2 testing using next-generation sequencing with a 25-gene panel","volume":"121","author":"Tung","year":"2015","journal-title":"Cancer"},{"key":"R35-20250802","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1001\/jamaoncol.2017.0424","article-title":"Associations between cancer predisposition testing panel genes and breast cancer","volume":"3","author":"Couch","year":"2017","journal-title":"JAMA Oncol"},{"key":"R36-20250802","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.humpath.2018.06.024","article-title":"Clinicopathologic characterization of breast carcinomas in patients with non-BRCA germline mutations: results from a single institution\u2019s high risk population","volume":"82","author":"Meiss","year":"2018","journal-title":"Hum Pathol"},{"key":"R37-20250802","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.breast.2016.05.006","article-title":"Women at high risk of breast cancer: molecular characteristics, clinical presentation and management","volume":"28","author":"Kleibl","year":"2016","journal-title":"Breast"},{"key":"R38-20250802","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.ygyno.2018.10.019","article-title":"Cancer susceptibility gene mutations in type I and II endometrial cancer","volume":"152","author":"Long","year":"2019","journal-title":"Gynecol Oncol"},{"key":"R39-20250802","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1002\/ijc.32389","article-title":"Screening for hereditary cancers in patients with endometrial cancer reveals a high frequency of germline mutations in cancer predisposition genes","volume":"145","author":"Tian","year":"2019","journal-title":"Int J Cancer"},{"key":"R40-20250802","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1126\/science.aan6733","article-title":"Mismatch-repair deficiency predicts response of solid tumors to PD-1 blockade","volume":"357","author":"Le","year":"2017","journal-title":"Science"},{"key":"R41-20250802","doi-asserted-by":"crossref","first-page":"3753","DOI":"10.1158\/1078-0432.CCR-18-4070","article-title":"FDA approval summary: pembrolizumab for the treatment of microsatellite instability-high solid tumors","volume":"25","author":"Marcus","year":"2019","journal-title":"Clin Cancer Res"},{"key":"R42-20250802","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1097\/PAS.0000000000000783","article-title":"PD-L1 expression in mismatch repair-deficient endometrial carcinomas, including Lynch syndrome-associated and MLH1 promoter hypermethylated tumors","volume":"41","author":"Sloan","year":"2017","journal-title":"Am J Surg Pathol"},{"key":"R43-20250802","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1038\/s41379-018-0039-1","article-title":"Indoleamine 2,3-dioxygenase in endometrial cancer: a targetable mechanism of immune resistance in mismatch repair-deficient and intact endometrial carcinomas","volume":"31","author":"Mills","year":"2018","journal-title":"Mod Pathol"},{"key":"R44-20250802","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1038\/s41379-019-0251-7","article-title":"TIM-3 in endometrial carcinomas: an immunotherapeutic target expressed by mismatch repair-deficient and intact cancers","volume":"32","author":"Moore","year":"2019","journal-title":"Mod Pathol"},{"key":"R45-20250802","doi-asserted-by":"crossref","first-page":"4473","DOI":"10.1158\/1078-0432.CCR-16-2655","article-title":"Immune microenvironment in microsatellite-instable endometrial cancers: Hereditary or sporadic origin matters","volume":"23","author":"Pakish","year":"2017","journal-title":"Clin Cancer Res"}],"container-title":["International Journal of Gynecological Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/PGP.0000000000000767","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,2]],"date-time":"2025-08-02T19:03:47Z","timestamp":1754161427000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/PGP.0000000000000767"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,11]]},"references-count":45,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1097\/pgp.0000000000000767","relation":{},"ISSN":["0277-1691"],"issn-type":[{"value":"0277-1691","type":"print"}],"subject":[],"published":{"date-parts":[[2021,2,11]]}}}